PRF Technologies Issues Letter to Shareholders Highlighting Strengthened Financial Position and Building Momentum Across Its Biotechnology and AI-Driven Energy Platforms

Rhea-AI Summary

PRF Technologies (Nasdaq: PRFX) reported in a shareholder letter that it raised $10 million on May 28, 2026 through its equity line facility, which the company says substantially strengthened its balance sheet and increased strategic flexibility for growth initiatives.

The biotechnology subsidiary LayerBio is completing operational and clinical preparations for a planned Phase 2 trial of OcuRing-K, an ocular implant used during cataract surgery, while lead candidate PRF-110 showed expanded preclinical data with sustained 72-hour analgesic activity versus an approved extended-release benchmark.

In renewable energy, DeepSolar validated its Predict platform with European market data, added Battery-to-Revenue Intelligence for storage assets, joined the NVIDIA Connect program and plans to showcase GridFeed at Energy Trading Week Europe 2026.

Positive

• $10 million raised via equity line on May 28, 2026
• Planned Phase 2 clinical trial preparations for OcuRing-K at LayerBio
• PRF-110 preclinical data show 72-hour sustained analgesic activity vs. benchmark
• DeepSolar Predict validated with real-world European market data
• DeepSolar platform expanded with Battery-to-Revenue Intelligence for storage assets
• DeepSolar joined NVIDIA Connect and will showcase GridFeed at major 2026 industry event

Negative

• None.

Market Context

-0.62% was the average move across PRF's AI-tagged historical events. That record adds mixed precede...

Analysis

-0.62% was the average move across PRF's AI-tagged historical events. That record adds mixed precedent to this shareholder letter's capital, clinical, and energy-platform updates; the main risk is that planned milestones remain execution-dependent.

Key Figures

New capital: $10 million Trial phase: Phase 2 Analgesic activity: 72-hour

3 metrics

New capital $10 million Raised through the company's equity line facility on May 28, 2026

Trial phase Phase 2 Planned clinical trial of OcuRing-K

Analgesic activity 72-hour Sustained activity demonstrated by PRF-110 in expanded preclinical results

Previous AI Reports

5 past events · Latest: Jul 15 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 15	AI platform expansion	Positive	+3.3%	Battery-to-Revenue Intelligence expanded optimization workflows into battery storage assets
Jul 08	AI platform validation	Positive	-5.2%	DeepSolar Predict completed initial validation using real-world European market data
May 28	AI commercial launch	Positive	+1.5%	DeepSolar Predict advanced toward planned commercial launch across renewable energy markets
Mar 27	Business update	Negative	-11.9%	The company reported a 2025 net loss and continued platform development
Nov 12	AI engine development	Positive	+9.3%	DeepSolar advanced an automated reporting engine for solar-asset analysis

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

AI-tagged historical reactions were mixed, with four aligned events and one divergence; the average move was -0.62%.

Key Terms

equity line facility, phase 2 clinical trial, sustained-release, extended-release

4 terms

equity line facility financial

"Raised $10 million through the Company's equity line facility"

An equity line facility is a financing arrangement that lets a company raise money over time by selling newly issued shares to an investor or through a market program, similar to drawing on a credit line but paid with stock instead of cash. It matters to investors because it provides the company with flexible access to cash for growth or obligations, but it can dilute existing shareholders’ ownership and affect the share price as new shares are issued.

phase 2 clinical trial medical

"preparations required to commence the planned Phase 2 clinical trial"

A phase 2 clinical trial is a research study that tests a new medical treatment or drug to see if it is effective and safe for a specific condition. It involves a larger group of people than earlier trials and helps determine whether the treatment should move forward to more extensive testing. For investors, successful phase 2 results can signal potential for future approval and commercial success, while setbacks may indicate challenges ahead.

sustained-release medical

"placing a sustained-release anti-inflammatory implant directly on the intraocular lens"

Sustained-release describes a drug formulation designed to release its active ingredient slowly over an extended period instead of all at once, like a time-release capsule that dissolves gradually. For investors, it matters because sustained-release products can improve patient convenience and adherence, extend a drug’s market life, reduce dosing frequency, and create competitive advantages that may affect sales, pricing power, and regulatory considerations.

extended-release medical

"an approved, commercially available extended-release benchmark"

Extended-release is a drug formulation designed to release its active ingredient slowly over an extended period so the medicine stays at steadier levels in the body and usually needs to be taken less often—think of a timed-release coffee versus sipping many short espressos. Investors care because extended-release versions can improve patient adherence, reduce side effects, and create product differentiation that supports higher pricing, longer commercial lifecycles, and clearer revenue visibility, while also attracting specific regulatory and manufacturing considerations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Interim CEO Efraim Cohen-Arazi Details $10 Million in New Capital, LayerBio's Preparations for the Planned Phase 2 Clinical Trial of OcuRing™-K, and DeepSolar's Advance Toward Commercial Launch

TEL AVIV, Israel, July 27, 2026 (GLOBE NEWSWIRE) -- PRF Technologies Ltd. (Nasdaq: PRFX) (“PRF”, “PRF Technologies” or the “Company”) today issued a Letter to Shareholders from Efraim Cohen-Arazi, Interim Chief Executive Officer.

First-Half 2026 and Recent Highlights:

• Raised $10 million through the Company's equity line facility, substantially strengthening the balance sheet
• LayerBio advancing the operational and clinical preparations required to commence the planned Phase 2 clinical trial of OcuRing™-K
• Reported expanded preclinical results for PRF-110, demonstrating sustained 72-hour analgesic activity comparable to an approved, commercially available extended-release benchmark
• DeepSolar validated its Predict™ platform with real-world European market data, expanded the platform with Battery-to-Revenue Intelligence, joined the NVIDIA Connect program and will showcase GridFeed™ at Energy Trading Week Europe 2026

Dear Fellow Shareholders,

As we move through the second half of 2026, I am excited to share an update on PRF Technologies' progress and the strategic priorities that are expected to guide the Company in the months ahead. Simply put: PRF today is stronger, better capitalized and moving with more momentum than it was just six months ago.

During the first half of 2026, we achieved a transformative milestone by significantly strengthening our financial position. We believe that this accomplishment provides PRF with increased strategic flexibility and positions us to execute our long-term growth strategy from a position of strength.

Strengthening Our Financial Foundation

On May 28, 2026, PRF raised $10 million through its equity line facility. This financing substantially strengthened our balance sheet and provides the resources necessary to accelerate our existing businesses while pursuing additional strategic growth opportunities.

We believe that our strengthened financial position allows us to focus on disciplined execution while maintaining the flexibility to capitalize on attractive opportunities as they arise.

Executing a Disciplined Growth Strategy

Our strategy remains centered on creating long-term shareholder value through disciplined capital allocation focused on the development of innovative technology businesses.

While we remain committed to advancing our existing biotechnology and renewable energy platforms, we are also evaluating strategic opportunities that we believe have the potential to accelerate growth and enhance shareholder value. These opportunities may include strategic partnerships, licensing arrangements, investments and selective acquisitions of complementary technologies or companies that align with our long-term vision.

We intend to pursue such opportunities with financial discipline and only where they strengthen our strategic position and have the potential to create sustainable long-term value for our shareholders.

Advancing Our Biotechnology Business

Our biotechnology majority-owned subsidiary, LayerBio, Inc., continues to make meaningful progress.

LayerBio is rapidly advancing the operational and clinical preparations required to commence the planned Phase 2 clinical trial of OcuRing™-K toward potential commercialization. We believe that OcuRing-K represents a paradigm shift in ocular drug delivery, placing a sustained-release anti-inflammatory implant directly on the intraocular lens during routine cataract surgery. — one of the most commonly performed surgical procedures in the world — with the potential to make recovery far more comfortable for patients and to deliver medication substantially more effectively than eye drops. We are actively evaluating additional opportunities of this kind to expand our portfolio.

Our lead product candidate, PRF-110, continues to advance. In June 2026, we reported expanded preclinical results from a head-to-head study in which PRF-110 demonstrated sustained 72-hour analgesic activity comparable to an approved, commercially available extended-release benchmark, along with slower systemic absorption and enhanced retention at the surgical site. We believe these results further validate our proprietary extended-release delivery platform and its potential to provide effective, opioid-sparing relief from post-operative pain.

Expanding Our Renewable Energy Platform

Our renewable energy business continues to advance the development of GridFeed™ and DeepSolar Predict™, our AI-powered technologies designed to improve renewable energy forecasting, optimize market participation and maximize revenue opportunities for renewable energy asset owners.

The momentum here is tangible. In recent weeks alone, DeepSolar successfully validated the Predict platform using real-world European market data, expanded the platform with Battery-to-Revenue Intelligence to address energy storage assets, joined the NVIDIA Connect program and announced that it will showcase GridFeed at Energy Trading Week Europe 2026, one of Europe's premier energy trading gatherings. We remain focused on enhancing our technology platform, expanding commercial applications and positioning these solutions for broader market adoption.

Looking Ahead

PRF Technologies enters the second half of 2026 with a substantially stronger financial position, a diversified portfolio of innovative technology businesses, real commercial momentum and increased strategic flexibility — a powerful foundation for long-term value creation.

Our priorities are clear: execute the upcoming clinical milestones at LayerBio, continue advancing our renewable energy technologies, evaluate disciplined strategic growth opportunities and deploy capital responsibly to maximize long-term shareholder value.

The Board of Directors and management remain committed to disciplined execution, prudent capital allocation and transparent communication with our shareholders as we continue building a stronger and more valuable company.

On behalf of the Board of Directors and our entire team, I would like to thank our shareholders for your continued confidence, trust and support.

We look forward to updating you on our continued progress in the months ahead.

Sincerely,

Efraim Cohen-Arazi
Interim Chief Executive Officer
PRF Technologies

About PRF Technologies

PRF Technologies (Nasdaq: PRFX) is a company focused on the reformulation of established therapeutics, and a developer of AI-driven energy optimization technologies through its DeepSolar platform. The Company’s pharmaceutical programs leverage a proprietary extended-release drug-delivery system intended to provide prolonged post-surgical pain relief while minimizing the need for repeated dosing and reducing reliance on opioids. Through DeepSolar, PRF also delivers advanced software solutions that enable both consumers and enterprises to monitor, forecast, and optimize energy consumption - particularly in solar-integrated environments. This dual business model reflects PRF’s strategic commitment to applying precision technology across high-impact sectors including healthcare and sustainable energy. For more information, please visit www.prf-tech.com.

Forward-Looking Statements

This press release contains forward-looking statements about PRF’s expectations, beliefs and intentions including with respect to statements related to the Company’s belief that raising $10 million through its equity line facility provides it with increased strategic flexibility and positions us to execute our long-term growth strategy from a position of strength, its belief that its strengthened financial position allows it to focus on disciplined execution while maintaining the flexibility to capitalize on attractive opportunities, creating long-term shareholder value through disciplined capital allocation focused on the development of innovative technology businesses, advancing its existing biotechnology and renewable energy platforms, LayerBio's preparations required to commence the planned Phase 2 clinical trial of OcuRing™-K, the continued development of PRF-110, the advancement of GridFeed™ and DeepSolar Predict™ toward planned commercial launch, and its evaluation of strategic opportunities that it believes have the potential to accelerate growth and enhance shareholder value. Forward-looking statements can be identified by the use of forward-looking words such as “believe”, “expect”, “intend”, “plan”, “may”, “should”, “could”, “might”, “seek”, “target”, “will”, “project”, “forecast”, “continue” or “anticipate” or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. These forward-looking statements are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of our control. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: our ability to continue as a going concern, our history of significant losses, our need to raise additional capital and our ability to obtain additional capital on acceptable terms, or at all; our dependence on the success of our initial product candidate, PRF-110, OcuRing™-K, LayerBio Inc.’s lead product candidate, and the commercialization of the DeepSolar solution; the outcomes of preclinical studies, clinical trials and other research regarding PRF-110, OcuRing™-K and future product candidates; our limited experience managing clinical trials; our ability to retain key personnel and recruit additional employees; our reliance on third parties for the conduct of clinical trials, product manufacturing and development; the impact of competition and new technologies; our ability to comply with regulatory requirements relating to the development and marketing of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights and our ability to operate our business without infringing the intellectual property rights of others; the overall global economic environment; our ability to develop an active trading market for our ordinary shares and whether the market price of our ordinary shares is volatile; our ability to maintain our listing on the Nasdaq Capital Market; and statements as to the impact of the political and security situation in Israel on our business. More detailed information about the risks and uncertainties affecting us is contained under the heading “Risk Factors” included in the Company’s most recent Annual Report on Form 20-F and in other filings that we have made and may make with the Securities and Exchange Commission in the future.

Contact:

Crescendo Communications, LLC
Tel: 212-671-1021
Email: prfx@crescendo-ir.com

Dr. Ehud Geller, Executive Chairman
PRF Technologies Ltd.
Tel: +972-54-4236711
Email: egeller@medicavp.com

FAQ

What did PRF Technologies (Nasdaq: PRFX) announce in its July 27, 2026 shareholder letter?

PRF Technologies announced a $10 million capital raise and progress across its biotechnology and AI-driven energy platforms. According to PRF Technologies, funds strengthen its balance sheet while LayerBio advances OcuRing-K toward Phase 2 and DeepSolar prepares its Predict and GridFeed solutions for broader commercialization.

How much new capital did PRF Technologies (PRFX) raise in the first half of 2026?

PRF Technologies raised $10 million on May 28, 2026 through its equity line facility. According to PRF Technologies, this financing substantially strengthened the balance sheet and is intended to support existing businesses while enabling selective strategic growth opportunities and disciplined capital deployment.

What is the status of LayerBio’s OcuRing-K Phase 2 trial under PRF Technologies (PRFX)?

LayerBio is advancing operational and clinical preparations for a planned Phase 2 OcuRing-K trial. According to PRF Technologies, OcuRing-K is designed as a sustained-release anti-inflammatory implant placed on the intraocular lens during cataract surgery to improve comfort and drug delivery.

What new preclinical results did PRF Technologies (PRFX) report for PRF-110?

PRF Technologies reported expanded preclinical results showing PRF-110 provided sustained 72-hour analgesic activity comparable to an approved extended-release benchmark. According to PRF Technologies, PRF-110 also showed slower systemic absorption and enhanced retention at the surgical site, supporting its extended-release pain management platform.

How is PRF Technologies’ DeepSolar platform progressing toward commercialization in 2026?

DeepSolar validated its Predict platform using real-world European market data and expanded it with Battery-to-Revenue Intelligence. According to PRF Technologies, DeepSolar also joined the NVIDIA Connect program and plans to showcase GridFeed at Energy Trading Week Europe 2026 to support broader adoption.

What are PRF Technologies’ (PRFX) strategic priorities for the second half of 2026?

PRF Technologies aims to execute key clinical milestones at LayerBio, advance its renewable energy technologies and pursue disciplined strategic opportunities. According to PRF Technologies, capital will be deployed responsibly to maximize long-term shareholder value while maintaining a diversified portfolio and stronger financial position.